Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Biochem Biophys Res Commun ; 533(4): 1021-1026, 2020 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-33012510

RESUMEN

Recently, a high number of copper derivatives has been evaluated as DNA-targeting metallodrugs, due to the lower toxicity and its potential to cleave DNA. Several strategies have been testing to develop metal compounds effective against tumour cells. In this work, the ternary copper (doxycycline)-(1,10-phenanthroline) complex [Cu(dox)(phen)]2+ was especially designed as an antitumoral drug, previously showing high cytotoxicity and DNA cleavage activity. We aimed to further investigate the in vitro cytotoxic activity in both tumoral and non-tumoral cells, in vitro genotoxic potential, and in vivo antitumor activity using BALB/C mouse injected with sarcoma S180 and Ehrlich cell lines. Our results indicated that this compound exhibits a moderate genotoxic potential, with selective growth inhibition of tumor cells, especially the murine melanoma B16F10. Its main mechanism of action seems to be through ROS generation. We have further shown a significant reduction of the implanted tumor size in the animal model, suggesting that this compound has great antitumoral potential against many tumor types. [Cu(dox)(phen)]2+ is selectively cytotoxic for melanoma B16F10 and showed high chemotherapeutic potential in vivo against implanted sarcoma S180 and Ehrlich ascites tumours.


Asunto(s)
Antineoplásicos/farmacología , Cobre/farmacología , Compuestos Organometálicos/farmacología , Animales , Carcinoma de Ehrlich/tratamiento farmacológico , Carcinoma de Ehrlich/metabolismo , Carcinoma de Ehrlich/patología , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Daño del ADN , Doxiciclina/análogos & derivados , Doxiciclina/farmacología , Diseño de Fármacos , Ensayos de Selección de Medicamentos Antitumorales , Técnicas In Vitro , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Ratones , Ratones Endogámicos BALB C , Células RAW 264.7 , Sarcoma 180/tratamiento farmacológico , Sarcoma 180/metabolismo , Sarcoma 180/patología , Tetraciclinas/farmacología
2.
Drug Chem Toxicol ; 41(1): 9-15, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28274136

RESUMEN

Amphotericin B (AmB) is an antifungal antibiotic extracted from Streptomyces nodosus. Its fungicidal activity depends primarily on its binding to the sterol group that is present in fungal membranes. In view of the toxicity of this drug, the purpose of this study was to evaluate its mutagenic, carcinogenic, and recombinogenic activity, based on the wing somatic mutation and recombination test (SMART) and the epithelial tumor detection test (wts) applied to Drosophila melanogaster. Larvae were chronically treated with different concentrations of AmB (0.01, 0.02, and 0.04 mg/mL). The results revealed that AmB is a promutagen exhibiting increase in the number of spots on individuals from high bioactivation (HB) cross with a high level of cytochrome P450. The results also indicate that the main genotoxic event induced by AmB is recombinogenicity. Homologous recombination can act as a determinant at different stages of carcinogenesis. For verification of carcinogenic potential of this compound, larvae from the wts/mwh and wts/ORR, flr3 were treated with the same three AmB concentrations used in the SMART assay. The results did not provide evidence that AmB has carcinogenic potential in wts/mwh individuals. However, individuals from wts/ORR, flr3 developed tumors at the highest concentration tested.


Asunto(s)
Anfotericina B/toxicidad , Antifúngicos/toxicidad , Transformación Celular Neoplásica/inducido químicamente , Proteínas de Drosophila/genética , Drosophila melanogaster/efectos de los fármacos , Recombinación Homóloga/efectos de los fármacos , Mutación , Neoplasias/inducido químicamente , Alas de Animales/efectos de los fármacos , Animales , Animales Modificados Genéticamente , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Relación Dosis-Respuesta a Droga , Proteínas de Drosophila/metabolismo , Drosophila melanogaster/embriología , Drosophila melanogaster/genética , Drosophila melanogaster/metabolismo , Regulación Neoplásica de la Expresión Génica , Genotipo , Larva/efectos de los fármacos , Larva/genética , Larva/metabolismo , Neoplasias/genética , Neoplasias/metabolismo , Fenotipo , Medición de Riesgo , Alas de Animales/metabolismo
3.
Genet Mol Biol ; 38(1): 101-6, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25983631

RESUMEN

Pantoprazole(®) is one of the leading proton pump inhibitors (PPIs) used in the treatment of a variety of diseases related to the upper gastrointestinal tract. However, studies have shown an increased risk of developing gastric cancer, intestinal metaplasia and hyperplasia of endocrine cells with prolonged use. In the present study, the somatic mutation and recombination test (SMART) was employed to determine the mutagenic effects of Pantoprazole on Drosophila melanogaster. Repeated treatments with Pantoprazole were performed on 72-hour larvae of the standard (ST) and high bioactivation (HB) crosses at concentrations of 2.5, 5.0, and 10.0 µM. In addition, doxorubicin (DXR) was administered at 0.4 mM, as a positive control. When administered to ST descendants, total number of spots were statistically significant at 2.5 and 5.0 µM concentrations. For HB descendants, a significant increase in the total number of spots was observed among the marked transheterozygous (MH) flies. Through analysis of balancer heterozygous (BH) descendants, recombinogenic effects were observed at all concentrations in descendants of the HB cross. In view of these experimental conditions and results, it was concluded that Pantoprazole is associated with recombinogenic effects in Drosophila melanogaster.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA